Principles of Antimicrobial Therapy

Overview of Antimicrobial Therapy

  • Definition of Antimicrobial Drugs: Chemicals used in the clinical treatment of infectious diseases caused by microorganisms.
  • Historical and Modern Clinical Significance:
    • Prior to the development and clinical deployment of antimicrobial therapies, large numbers of human patients died from common microbial infections.
    • Following the widespread availability of antimicrobials, many formerly life-threatening illnesses became easily treatable.
    • The continued clinical utility of many frontline antimicrobial medications is declining due to the emergence and rapid dissemination of resistant microbial strains.
  • Major Classes of Antimicrobial Drugs by Target Organism:
    • Antibacterial drugs: Specifically target and combat bacterial pathogens.
    • Antifungal drugs: Specifically target fungal pathogens.
    • Antiprotozoan drugs: Specifically target pathogenic single-celled protozoa.
    • Antihelminthic drugs: Specifically target parasitic worms (helminths).
    • Antiviral drugs: Specifically interfere with viral replication cycles.

Key Terminology in Antimicrobial Pharmacotherapy

  • Acquired Resistance: Resistance to an antimicrobial agent that develops within a microorganism through spontaneous genetic mutation or through the acquisition of new foreign genetic material.
  • Antibacterial Drug: An antimicrobial drug formulated specifically to treat infectious diseases caused by bacteria.
  • Antibiotic: A chemical compound naturally produced by certain living molds (fungi) and bacteria that inhibits the growth of or actively kills other microorganisms.
  • Antimicrobial Drug (or Antimicrobial): Any chemical agent that inhibits the growth of or kills microorganisms. This overarching term encompasses naturally occurring antibiotics as well as chemically synthesized or modified agents.
  • Antiviral Drug: A drug that interferes directly with the intracellular replication machinery of viruses. All antiviral drugs are chemically synthesized in laboratories; none are naturally occurring antibiotics.
  • Bactericidal Drug: An antimicrobial medication that actively kills bacterial cells.
  • Bacteriostatic Drug: An antimicrobial medication that inhibits the growth, proliferation, and reproduction of bacterial cells without necessarily killing them, allowing the host immune defenses to clear the infection.
  • Broad-Spectrum Antimicrobial: An antimicrobial agent that demonstrates clinical efficacy against a wide range of diverse microorganisms, frequently encompassing both Gram-positive and Gram-negative bacteria.
  • Chemotherapeutic Agent: Any chemical compound administered to a patient to treat a disease.
  • Intrinsic Resistance: Resistance to an antimicrobial drug that is due to an inherent, preexisting structural or physiological characteristic of the microorganism.
  • Narrow-Spectrum Antimicrobial: An antimicrobial agent that demonstrates clinical efficacy against only a limited, specific range of microorganisms.
  • R Plasmid: A bacterial plasmid (extrachromosomal circular DNA element) that encodes genetic determinants of resistance to one or more antimicrobial drugs.
  • Therapeutic Index: A quantitative clinical safety ratio expressing the relative toxicity of a chemotherapeutic drug, defined as the lowest dose toxic to the patient divided by the therapeutic dose used to treat the infection.

Discovery and Historical Context of Natural Antibiotics

  • Alexander Fleming:
    • Scottish biologist, pharmacologist, and botanist who authored seminal scientific papers in the fields of bacteriology, immunology, and chemotherapy.
    • Identified and discovered the natural antimicrobial enzyme lysozyme in 19231923.
    • Discovered the natural antibiotic compound penicillin from the mold species Penicillium notatum in 19281928.

Alexander Fleming examining a culture plate

  • The Mechanism of Penicillin Discovery:
    • Reported in the British Journal of Experimental Pathology (Vol. X, No. 33).
    • Fleming observed a contaminated agar culture plate containing colonies of Staphylococcus bacteria that had been compromised by a fungal mold colony identified as Penicillium.
    • In the immediate neighborhood surrounding the Penicillium colony, staphylococcal bacterial colonies showed marked growth dissolution, clearing, and cell breakdown via lysis.
    • Bacterial colonies located farther away from the Penicillium growth displayed normal colonial morphology, demonstrating that the mold produced and diffused a soluble antibacterial substance capable of killing bacteria.

Culture plate showing dissolution of staphylococcal colonies near a Penicillium colony

Industrial Production and Classification by Drug Origin

  • Ecological Origin of Natural Antibiotics:
    • The overwhelming majority of modern naturally derived antibiotics originate from species of microorganisms that naturally inhabit the soil, where they produce these compounds to compete with rival microbial species.
  • Commercial Step-by-Step Production Process:
    • Step 1: Select a high-yield microbial producer strain and inoculate it into liquid nutrient broth inside industrial fermenters.
    • Step 2: Continuously monitor bacterial or fungal growth; when the maximum concentration of antibiotic is reached in the medium, extract the active compound from the broth.
    • Step 3: Purify the extracted compound through specialized biochemical separation procedures.
    • Step 4: Chemically alter the purified compound to increase molecular stability, decrease toxicity, or broaden its antimicrobial spectrum.
  • Classification by Origin and Synthesis:
    • Natural Antibiotics: Unmodified natural metabolic products obtained mainly from fungal sources (such as penicillin) or soil bacteria.
    • Semi-Synthetic Drugs: Naturally derived chemical compounds that are chemically altered in a laboratory setting to enhance antimicrobial effectiveness, lower patient toxicity, and enhance molecular stability.
    • Synthetic Drugs: Antimicrobial compounds entirely designed and synthesized de novo in chemical laboratories to maximize efficacy and minimize physiological toxicity to the patient.

Pharmacodynamic Principles: Selective Toxicity and Dosing Indices

  • Selective Toxicity:
    • The fundamental prerequisite of an antimicrobial drug to cause significantly greater biochemical damage and harm to the targeted invading microorganism than to the host tissues.
    • Achieved by targeting cellular structures, enzymes, or metabolic pathways that are unique to the pathogen and absent or markedly different in human host cells.

Selective toxicity balance and chemotherapeutic index equation

  • Chemotherapeutic Index (Therapeutic Index):
    • A quantitative measurement of the margin of clinical safety for an antimicrobial compound:   Chemotherapeutic index=Lowest dose toxic to patientDose typically used for therapy\text{Chemotherapeutic index} = \frac{\text{Lowest dose toxic to patient}}{\text{Dose typically used for therapy}}
    • A higher chemotherapeutic index indicates a safer medication with a wider therapeutic window, whereas a low index indicates that the therapeutic dose is close to the toxic threshold.
  • Antimicrobial Action (Bactericidal vs. Bacteriostatic):
    • Bacteriostatic action: Agents arrest the reproductive cycles and growth kinetics of bacterial populations without destroying them directly; host cellular immunity must eradicate the static bacterial population.
    • Bactericidal action: Agents directly initiate bacterial cell death and lysis; used in situations where host defenses cannot clear the pathogen or in acute life-threatening infections.
    • Compounds categorized as antibiotics, topical antiseptics, and environmental disinfectants can all exhibit bactericidal properties.

Spectrum of Activity of Antimicrobial Drugs

  • Variation in Spectrum: Antimicrobial agents differ substantially regarding the specific taxonomic range of microbes they kill or inhibit.
    • Narrow-Spectrum Antimicrobials: Effective against only a restricted, defined subset of microorganisms. Clinical advantage includes minimizing collateral disruption to beneficial host normal flora.
    • Broad-Spectrum Antimicrobials: Effective against an extensive spectrum of microbial taxa, typically targeting both Gram-positive and Gram-negative bacterial species simultaneously.

Spectrum of activity of major antimicrobial drug classes

  • Pathogen Taxa and Corresponding Antibiotic Spectra:
    • Penicillins: Primarily active across Gram-positive bacteria and extending into Chlamydiae.
    • Sulfonamides, Cephalosporins, Quinolones, and Carbapenems: Intermediately broad agents active against both Gram-negative bacteria and Gram-positive bacteria.
    • Streptomycin: Active against Mycobacteria and Gram-negative bacteria.
    • Tetracyclines: Classical broad-spectrum agents effective across Gram-negative bacteria, Gram-positive bacteria, Chlamydiae, and Rickettsiae.
    • Isoniazid: Distinct narrow-spectrum agent with activity confined strictly to Mycobacteria.
    • Polymyxin: Distinct narrow-spectrum agent acting exclusively against Gram-negative bacteria.
    • Vancomycin: Narrow-spectrum glycopeptide agent active strictly against Gram-positive bacteria.

Combinatorial Therapy and Host Adverse Effects

  • Drug Combination Dynamics:
    • Antimicrobials are frequently co-administered to combat mixed or severe refractory infections.
    • Synergistic combinations: The specific pharmacological action of one antimicrobial drug significantly enhances or potentiates the therapeutic activity of the second drug.
    • Antagonistic combinations: The biochemical action or physiological effect of one drug actively counteracts, diminishes, or interferes with the antimicrobial efficacy of another.
  • Adverse Clinical Effects on the Host:
    • Allergic Reactions: Drug hypersensitivities mediated by host immune activation, ranging from mild skin eruptions to systemic anaphylaxis.
    • Toxic Effects: Direct organ system toxicity or cellular damage caused by antimicrobials when administered at high systemic concentrations or through inherent tissue-specific toxicity.
    • Suppression of Normal Flora: Broad-spectrum agents eradicate native commensal bacterial populations within the gastrointestinal, respiratory, or genitourinary tracts; the disruption of protective ecological niches allows opportunistic pathogens to proliferate rapidly to high numbers, causing secondary superinfections.

Laboratory Determination of Susceptibility: The Kirby-Bauer Method

  • Kirby-Bauer Agar Disk Diffusion Assay: Standardized laboratory method used to evaluate the in vitro antimicrobial susceptibility of isolated bacterial pathogens.
  • Step-by-Step Procedure:
    • Step 1: Inoculate and spread the bacterial test isolate evenly over the entire surface of an agar plate to establish a continuous lawn of growth.
    • Step 2: Place 1212 paper filter disks, each impregnated with a known, standardized concentration of a different antimicrobial drug, onto the agar surface.
    • Step 3: Incubate the agar plate at physiological temperature. As the bacteria grow, the antimicrobials diffuse radially outward into the agar from the disks, creating decreasing concentration gradients.
    • Step 4: Inspect the plate for clear zones of inhibition around the disks where the diffused drug concentration prevented bacterial growth or induced cell lysis.
    • Step 5: Measure the diameter of the clear zone of inhibition for each drug in millimeters and compare the values against standardized clinical susceptibility interpretation charts to categorize the isolate as sensitive, intermediate, or resistant.

Major Structural and Functional Classes of Antibiotics

  • Properties of Key Antibacterial Drug Classes:
    • Beta-Lactams (Natural Penicillins and Cephalosporins):
    • Representative Drugs: Penicillin G, Cephalothin.
    • Biological Sources: Produced naturally by Penicillium notatum and Cephalosporium species.
    • Antimicrobial Spectrum: Gram-positive bacteria.
    • Mode of Action: Competitive inhibition of transpeptidase enzymes involved in the final steps of peptidoglycan synthesis, blocking cell wall construction and murein assembly.
    • Semisynthetic Beta-Lactams:
    • Representative Drugs: Ampicillin, Amoxicillin.
    • Biological Sources: Chemically modified aminopenicillin derivatives.
    • Antimicrobial Spectrum: Broad-spectrum activity against both Gram-positive and Gram-negative bacteria.
    • Mode of Action: Inhibits cell wall peptidoglycan assembly and murein cross-linking.
    • Beta-Lactamase Inhibitors / Combinations:
    • Representative Drug / Combination: Augmentin, consisting of the beta-lactamase inhibitor clavulanic acid co-formulated with amoxicillin.
    • Biological Source: Clavulanic acid is isolated from Streptomyces clavuligerus.
    • Antimicrobial Spectrum: Effective against Gram-positive and Gram-negative bacteria, including strains that produce beta-lactamase enzymes.
    • Mode of Action: Clavulanic acid acts as a suicide inhibitor of bacterial beta-lactamase enzymes, protecting the companion beta-lactam ring of amoxicillin from enzymatic degradation.
    • Monobactams:
    • Representative Drug: Aztreonam.
    • Biological Source: Derived from the bacterium Chromobacterium violaceum.
    • Antimicrobial Spectrum: Gram-positive and Gram-negative bacteria.
    • Mode of Action: Selective inhibition of penicillin-binding proteins in bacterial cell wall peptidoglycan synthesis.
    • Carbapenems:
    • Representative Drug: Imipenem.
    • Biological Source: Derived from Streptomyces cattleya.
    • Antimicrobial Spectrum: Very broad coverage against Gram-positive and Gram-negative bacteria.
    • Mode of Action: Inhibits steps in cell wall peptidoglycan synthesis and murein assembly; exhibits resistance to cleavage by many standard beta-lactamases.
  • Classification by Chemical Structure:
    • Penicillins
    • Cephalosporins
    • Macrolides and azalides
    • Fluoroquinolones (Quinolones)
    • Tetracyclines
    • Aminoglycosides
    • Sulphonamides
    • Glycopeptides
    • Oxazolidinones
    • Amphenicols
    • Lincosamides
    • Carbapenems
    • Nitroimidazoles

Targets and Challenges of Antifungal Chemotherapy

  • Selective Toxicity Constraints in Fungi:
    • Because fungi are eukaryotic organisms, finding targets that provide selective toxicity is substantially more difficult than in prokaryotic bacteria.
    • Host human cells and fungal pathogens share homologous eukaryotic cellular architecture, protein translation systems, and cellular metabolic machinery, which elevates the risk of host toxic adverse effects.
  • Primary Therapeutic Targets in Fungal Pathogens:
    • Agents Affecting Fungal Sterols: Exploit differences between human cholesterol and fungal ergosterol; disrupt fungal cytoplasmic membrane stability and permeability.
    • Agents Affecting Fungal Cell Walls: Exploit the unique carbohydrate polymers of the fungal cell wall, such as beta-glucans and chitin, which are completely absent in mammalian cells.
    • Agents Inhibiting Nucleic Acids: Disentangle or halt fungal-specific enzymatic pathways involved in RNA and DNA nucleotide biosynthesis.

Mechanisms, Evolution, and Mitigation of Antimicrobial Resistance

  • Evolutionary Trajectory of Resistance:
    • Resistance to antimicrobial drugs restricts and threatens the clinical longevity of all known antimicrobial classes.
    • When Penicillin G was initially introduced into clinical use, only 3%3\% of targeted bacterial isolates exhibited natural resistance.
    • In modern clinical environments, over 90%90\% of targeted bacterial strains have developed resistance to Penicillin G.
  • Primary Genetic Mechanisms of Resistance:
    • Spontaneous Mutations: Random nucleic acid base changes that occur continuously during chromosomal DNA replication in dividing bacterial cells.
    • Horizontal Gene Transfer: Rapid acquisition of pre-formed resistance determinants from other bacteria, mediated primarily through conjugative transfer of antibiotic resistance-encoding R-plasmids via bacterial sex pili.

Darwinian selection and population dynamics of antibiotic resistance

  • Population Dynamics of Antibiotic Selection:
    • Initial Baseline Population (A): In an untreated bacterial population, a small subset of bacterial cells naturally possess genes conferring resistance within their genomes; in the absence of antibiotic exposure, these genes offer no survival advantage and remain unselected.
    • Early to Late Treatment Phase (B): When exposed to an antibiotic, drug-sensitive bacterial cells are progressively killed; resistant cells survive and express active resistance mechanisms.
    • Post-Treatment Clonal Expansion (C): Surviving drug-resistant bacteria multiply without ecological competition, filling the biological niche with large resistant populations; the specific antibiotic is rendered clinically useless against the newly established population.
  • Multidisciplinary Responsibilities to Slow Resistance:
    • Responsibilities of Physicians: Accurately isolate and identify the specific pathogenic microbe prior to initiating therapy; prescribe appropriate narrow-spectrum antimicrobials; instruct and educate patients on correct drug administration protocols.
    • Responsibilities of Patients: Comply strictly with physician prescriptions; complete the full course of therapy; avoid self-medicating with unprescribed leftover antimicrobials.
    • Public Education: Improve public awareness of the appropriate use and physiological limitations of antibiotics; emphasize that antibacterial medications are completely ineffective against viral pathogens (such as common cold and flu viruses).
    • Global Impact and Oversight:
    • Because resistant bacterial strains move between geographical regions through international travel, resistance anywhere represents a global threat.
    • Regulate the over-the-counter, non-prescription sale of antimicrobials permitted in certain countries.
    • Restrict the routine non-therapeutic inclusion of sub-inhibitory doses of antibiotics in animal agricultural feed, which generates vast reservoirs of resistant bacterial strains within animal intestinal microbiomes.
  • Future Research Approaches:
    • Identification and characterization of novel physiological targets within pathogenic microbes.
    • Systematic bioprospecting and chemical synthesis to discover completely unique classes of antimicrobial agents.